Skip to main content
. 2022 Jun 18;8(5):e10351. doi: 10.1002/btm2.10351

FIGURE 6.

FIGURE 6

EcN‐GLP‐1 improved 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP)‐induced gut microbiota dysbiosis in mice. EcN‐GLP‐1 had no impacts on the Chao1 (a) and Simpson (b) indices of gut microbiota. (c) PCoA analysis of gut microbiota. (d) Barplots of the relative abundance of gut bacteria at the phyla level. The relative abundance of Verrucomicrobia (e) and Proteobactria (f) at the phylum level. (g) Barplots of the relative abundance of gut bacteria at the genus level. The relative abundance of Akkermansia (h), Oscillospira (i), and Prevotella (j). C, The normal control group; M, the MPTP‐induced Parkinson's disease (PD) model group; ME, the EcN‐GLP‐1 treatment group; MG, the exenatide treatment group; MN, the EcN treatment group. Five fecal samples of each group were randomly selected for 16S rRNA sequencing and bioinformatic analysis. Data were presented as means ± SD. Multiple Comparisons test, *p < 0.05, **p < 0.01, ns and no asterisk indicate no significant difference (p > 0.05)